In conclusion, the present pharmacogenetics clinical trial with a PROBE-design demonstrated that NAT2 genotype-guided dosing stratification of INH could improve treatment outcomes in patients with drug-sensitive tuberculosis. The gene discussed is NAT2; the disease is tuberculosis.